Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has scheduled its second quarter 2025 financial results announcement for Monday, August 11, 2025.

The company will host a conference call and audio webcast at 8:00 a.m. ET on the same day. Investors can access the call via phone at (800) 836-8184 (local) or (646) 357-8785 (international). A live webcast with accompanying slides will be available on the company's investor relations website.

-- Conference Call Scheduled for Monday, August 11, 2025, at 8:00 a.m. ET --

NEWTON, Mass., Aug. 5, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2025 financial results on Monday, August 11, 2025. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Monday, August 11, 2025, to discuss the financial results and other company updates.

To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first­in­class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex­U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-report-second-quarter-2025-financial-results-on-august-11-2025-302520844.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

When will Karyopharm (KPTI) report Q2 2025 earnings?

Karyopharm will report its Q2 2025 financial results on Monday, August 11, 2025.

How can investors join Karyopharm's Q2 2025 earnings call?

Investors can join by dialing (800) 836-8184 (local) or (646) 357-8785 (international), or watch the webcast on the company's investor relations website.

What time is Karyopharm's Q2 2025 earnings call?

The earnings conference call and webcast will begin at 8:00 a.m. ET on Monday, August 11, 2025.

Where can I find Karyopharm's Q2 2025 earnings presentation slides?

The presentation slides will be available under the 'Events & Presentations' section of Karyopharm's investor relations website at investors.karyopharm.com.